NASDAQ:CANC Tema Oncology ETF (CANC) Price, Holdings, & News $23.97 -0.33 (-1.36%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$24.09 +0.12 (+0.50%) As of 05/30/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema Oncology ETF (NASDAQ:CANC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tema Oncology ETF alerts:Sign Up Key Stats Today's Range$23.43▼$24.2850-Day Range$20.98▼$25.3552-Week Range$20.10▼$30.11Volume14,962 shsAverage Volume12,088 shsMarket Capitalization$64.96 millionAssets Under Management$67.72 millionDividend Yield3.00%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.Read More… Tema Oncology ETF ExpensesTypeCANCTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.48%0.42%0.52%Total Expense0.99%0.73%0.72%0.68%0.71%Fee Waiver-0.24%-0.71%-0.49%-0.29%-0.54%Net Expense0.75%0.60%0.63%0.62%0.60% Receive CANC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Oncology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address CANC ETF News HeadlinesNo headlines for this company have been tracked by MarketBeat.com CANC ETF - Frequently Asked Questions How have CANC shares performed this year? Tema Oncology ETF's stock was trading at $24.31 at the start of the year. Since then, CANC stock has decreased by 1.4% and is now trading at $23.97. View the best growth stocks for 2025 here. Who are Tema Oncology ETF's major shareholders? Top institutional shareholders of Tema Oncology ETF include Jane Street Group LLC (0.33%) and Banque Transatlantique SA (0.06%). How do I buy shares of Tema Oncology ETF? Shares of CANC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema Oncology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Oncology ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NICE (NICE) and Intellia Therapeutics (NTLA). Fund Details IssuerTema Global Fund NameTema Oncology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CANC Inception Date8/15/2023 Fund ManagerDavid Song WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings51 Fund Statistics Assets Under Management$67.72 million Average Daily Volume$0.00 Discount/Premium0.20% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest3,900 shs Miscellaneous Outstanding Shares2,710,000Beta1.11 Creation Unit10,000 Creation Fee$500.00 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report Top 10 CANC HoldingsRevolution Medicines (NASDAQ:RVMD)Holding Weight: 6.02%Roche (OTCMKTS:RHHBY)Holding Weight: 5.02%Eli Lilly and Company (NYSE:LLY)Holding Weight: 4.67%Exelixis (NASDAQ:EXEL)Holding Weight: 4.54%Novartis AGHolding Weight: 4.27%AstraZeneca PLCHolding Weight: 4.25%Nuvalent (NASDAQ:NUVL)Holding Weight: 4.03%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 4.02%Summit Therapeutics (NASDAQ:SMMT)Holding Weight: 3.76%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 3.72%Full Holdings DetailsCANC Sector ExposureCANC Industry Exposure This page (NASDAQ:CANC) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.